新型冠状病毒二次感染与免疫力相关性分析的研究进展
Research Progress on the Correlation Analysis between Reinfections of SARS-CoV-2 and Immunity
DOI: 10.12677/acm.2024.1451694, PDF,    科研立项经费支持
作者: 郭佳宜*：滨州医学院第一临床医学院，山东 烟台；王 统*：滨州医学院卫生管理学院，山东 烟台；时耿林, 李 雪, 付 强#：滨州医学院药学院，山东 烟台；孙银恒, 欧 洋：滨州医学院特殊教育与康复学院，山东 烟台
关键词: 新型冠状病毒(SARS-CoV-2)；免疫力；二次感染；抗体；疫苗开发；SARS-CoV-2； Immunity； Reinfection； Antibodies； Vaccine Development
摘要: 由新型冠状病毒(SARS-CoV-2)引发的COVID-19在全球范围内持续肆虐，严重威胁公共卫生安全。本文从二次感染概述、免疫力与二次感染的相关性、疫苗开发和策略调整、未来研究方向及挑战等方面进行综述，以期为再感染预防、疫情防控策略制定及疫苗开发提供参考。
Abstract: The COVID-19 pandemic, caused by SARS-CoV-2, continues to rampage worldwide, posing a grave threat to public health security. This article provides a comprehensive review on reinfections, the correlation between immunity and reinfections, the development of vaccines and strategy adjustments, and future research directions and challenges, aiming to provide insights for the prevention of reinfection, development of epidemic prevention and control strategies, and vaccine development.
文章引用：郭佳宜, 王统, 时耿林, 孙银恒, 欧洋, 李雪, 付强. 新型冠状病毒二次感染与免疫力相关性分析的研究进展[J]. 临床医学进展, 2024, 14(5): 2354-2363. https://doi.org/10.12677/acm.2024.1451694

参考文献

[1] WHO (2024) Number of COVID-19 Cases Reported to WHO (Cumulative Total).
https://data.who.int/dashboards/covid19/cases?n=c
[2] WHO (2024) Number of COVID-19 Deaths Reported to WHO (Cumulative Total).
https://data.who.int/dashboards/covid19/deaths?n=c
[3] Bowe, B., Xie, Y. and Al-Aly, Z. (2022) Acute and Postacute Sequelae Associated with SARS-CoV-2 Reinfection. Nature Medicine, 28, 2398-2405. [Google Scholar] [CrossRef] [PubMed]
[4] Batisse, D., Benech, N., Botelho-Nevers, E., et al. (2020) Clinical Recurrences of COVID-19 Symptoms after Recovery: Viral Relapse, Reinfection or Inflammatory Rebound? Journal of Infection, 81, 816-846.
[5] Hansen, C.H., Michlmayr, D., Gubbels, S.M., et al. (2021) Assessment of Protection against Reinfection with SARS-CoV-2 among 4 Million PCR-Tested Individuals in Denmark in 2020: A Population-Level Observational Study. The Lancet, 397, 1204-1212. [Google Scholar] [CrossRef] 
[6] Anka, A.U., Tahir, M.I., Abubakar, S.D., et al. (2020) Coronavirus Disease 2019 (COVID-19): An Overview of the Immunopathology, Serological Diagnosis and Management. Scandinavian Journal of Immunology, 93, e12998. [Google Scholar] [CrossRef] [PubMed]
[7] Tillett, R.L., Sevinsky, J.R., Hartley, P.D., et al. (2021) Genomic Evidence for Reinfection with SARS-CoV-2: A Case Study. The Lancet Infectious Diseases, 21, 52-58. [Google Scholar] [CrossRef] 
[8] Bešević, J., Lacey, B., Callen, H., et al. (2024) Persistence of SARS-CoV-2 Antibodies over 18 Months Following Infection: UK Biobank COVID-19 Serology Study. Journal of Epidemiology and Community Health, 78, 105-108. [Google Scholar] [CrossRef] [PubMed]
[9] 新冠二次感染更可能无症状? 《柳叶刀》发表大规模医护人员研究[Z/OL].
https://www.chinacdc.cn/gwxx/202104/t20210422_229974.html
[10] Bailie, C.R., Tseng, Y.Y., Carolan, L., et al. (2022) Trend in Sensitivity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Serology One Year after Mild and Asymptomatic Coronavirus Disease 2019 (COVID-19): Unpacking Potential Bias in Seroprevalence Studies. Clinical Infectious Diseases, 75, E357-E360. [Google Scholar] [CrossRef] [PubMed]
[11] Almadhi, M., Alsayyad, A.S., Conroy, R., et al. (2022) Epidemiological Assessment of SARS-CoV-2 Reinfection. International Journal of Infectious Diseases, 123, 9-16. [Google Scholar] [CrossRef] [PubMed]
[12] Hall, V.J., Foulkes, S., Saei, A., et al. (2021) COVID-19 Vaccine Coverage in Health-Care Workers in England and Effectiveness of BNT162b2 MRNA Vaccine against Infection (SIREN): A Prospective, Multicentre, Cohort Study. The Lancet, 397, 1725-1735. [Google Scholar] [CrossRef] 
[13] Tartof, S.Y., Slezak, J.M., Fischer, H., et al. (2021) Effectiveness of MRNA BNT162b2 COVID-19 Vaccine up to 6 Months in a Large Integrated Health System in the USA: A Retrospective Cohort Study. The Lancet, 398, 1407-1416. [Google Scholar] [CrossRef] 
[14] Cromer, D., Juno, J.A., Khoury, D., et al. (2021) Prospects for Durable Immune Control of SARS-CoV-2 and Prevention of Reinfection. Nature Reviews Immunology, 21, 395-404. [Google Scholar] [CrossRef] [PubMed]
[15] Hacisuleyman, E., Hale, C., Saito, Y., et al. (2021) Vaccine Breakthrough Infections with SARS-CoV-2 Variants. New England Journal of Medicine, 384, 2212-2218. [Google Scholar] [CrossRef] 
[16] Markov, P.V., Ghafari, M., Beer, M., et al. (2023) The Evolution of SARS-CoV-2. Nature Reviews Microbiology, 21, 361-379. [Google Scholar] [CrossRef] [PubMed]
[17] 卓家同. 新型冠状病毒疫苗激发T淋巴细胞免疫作用的优势探讨[J]. 上海预防医学, 2024, 36(4): 409-414.
[18] 史庆丰, 高晓东, 胡必杰. Delta新冠病毒变异株的特性及流行现状与防控研究进展[J]. 中华医院感染学杂志, 2021, 31(24): 3703-3707.
[19] 朱瑶, 韦意娜, 孙畅, 等. 新型冠状病毒肺炎疫苗研究进展[J]. 预防医学, 2021, 33(2): 143-148.
[20] Primorac, D., Vrdoljak, K., Brlek, P., et al. (2022) Adaptive Immune Responses and Immunity to SARS-CoV-2. Frontiers in Immunology, 13, Article ID: 848582. [Google Scholar] [CrossRef] [PubMed]
[21] 王勋, 王鹏飞. 应对新冠病毒突变株的疫苗研究进展[J]. 张江科技评论, 2021(6): 35-37.
[22] 汪宏波, 张进祥. 新型冠状病毒灭活疫苗接种医疗保障专家共识(2021版) [J]. 医药导报, 2021, 40(9): 1169-1175.
[23] Tregoning, J.S., Flight, K.E., Higham, S.L., et al. (2021) Progress of the COVID-19 Vaccine Effort: Viruses, Vaccines and Variants versus Efficacy, Effectiveness and Escape. Nature Reviews Immunology, 21, 626-636. [Google Scholar] [CrossRef] [PubMed]
[24] 中国疾病预防控制中心. 全国新型冠状病毒感染疫情情况[Z/OL]. 2024.
https://www.chinacdc.cn/jkzt/crb/zl/szkb_11803/jszl_13141/202404/t20240410_276046.html, 2024-04-26.
[25] 陈恩富. 疫苗时代新型冠状病毒肺炎疫情防控策略[J]. 预防医学, 2021, 33(3): 221-225.
[26] Huang, C., Wang, Y., Li, X., et al. (2020) Clinical Features of Patients Infected with 2019 Novel Coronavirus in Wuhan, China. The Lancet, 395, 497-506. [Google Scholar] [CrossRef] 
[27] Wu, Z. and McGoogan, J.M. (2020) Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases from the Chinese Center for Disease Control and Prevention. JAMA, 323, 1239-1242. [Google Scholar] [CrossRef] [PubMed]
[28] Zhang, X., Tan, Y., Ling, Y., et al. (2020) Viral and Host Factors Related to the Clinical Outcome of COVID-19. Nature, 583, 437-440. [Google Scholar] [CrossRef] [PubMed]
[29] 李元丰, 吴天准, 陈顺琦, 等. 新冠肺炎遗传易感基因的研究进展[J]. 遗传, 2023, 45(11): 963-975.
[30] 杜婷婷. 劳动年龄人口新冠肺炎死亡率的性别差异研究[D]: [硕士学位论文]. 成都: 西南财经大学, 2022.
[31] 熊金蓉, 朱耀国, 刘胜军, 等. 不同性别新型冠状病毒肺炎患者临床特征的比较[J]. 武汉大学学报(医学版), 2021, 42(1): 15-18.
[32] Goldstein, E., Lipsitch, M. and Cevik, M. (2021) On the Effect of Age on the Transmission of SARS-CoV-2 in Households, Schools, and the Community. The Journal of Infectious Diseases, 223, 362-369. [Google Scholar] [CrossRef] [PubMed]
[33] 牛翊霖, 张纯, 曹雯煜, 等. 年龄因素对新型冠状病毒易感性的影响[J]. 新发传染病电子杂志, 2022, 7(3): 19-24.
[34] Zhang, J.-Y., Wang, X.-M., Xing, X., et al. (2020) Single-Cell Landscape of Immunological Responses in Patients with COVID-19. Nature Immunology, 21, 1107-1118. [Google Scholar] [CrossRef] [PubMed]
[35] 戴靖榕, 肖宝, 李霖, 等. 影响老年新型冠状病毒感染患者院内死亡的因素及风险预测模型的构建[J]. 基础医学与临床, 2024, 44(1): 92-97.
[36] Chen, J., Wang, P., Yuan, L., et al. (2022) A Live Attenuated Virus-Based Intranasal COVID-19 Vaccine Provides Rapid, Prolonged, and Broad Protection against SARS-CoV-2. Science Bulletin, 67, 1372-1387. [Google Scholar] [CrossRef] [PubMed]
[37] Monzon-Posadas, W.O., Zorn, J., Peters, K., et al. (2023) Longitudinal Monitoring of MRNA-Vaccine-Induced Immunity against SARS-CoV-2. Frontiers in Immunology, 14, Article ID: 1066123. [Google Scholar] [CrossRef] [PubMed]
[38] Fiolet, T., Kherabi, Y., MacDonald, C.-J., et al. (2022) Comparing COVID-19 Vaccines for Their Characteristics, Efficacy and Effectiveness against SARS-CoV-2 and Variants of Concern: A Narrative Review. Clinical Microbiology and Infection, 28, 202-221. [Google Scholar] [CrossRef] [PubMed]
[39] Zhu, F., Zhuang, C., Chu, K., et al. (2022) Safety and Immunogenicity of a Live-Attenuated Influenza Virus Vector-Based Intranasal SARS-CoV-2 Vaccine in Adults: Randomised, Double-Blind, Placebo-Controlled, Phase 1 and 2 Trials. The Lancet Respiratory Medicine, 10, 749-760. [Google Scholar] [CrossRef] 
[40] 联合国. 世卫组织: 新冠病毒传播与其他呼吸道疾病叠加, 各国需用好防治工具[Z/OL]. 2024.
https://news.un.org/zh/story/2024/01/1125712, 2024-04-26.
[41] Li, M., Wang, H., Tian, L., et al. (2022) COVID-19 Vaccine Development: Milestones, Lessons and Prospects. Signal Transduction and Targeted Therapy, 7, Article No. 146. [Google Scholar] [CrossRef] [PubMed]
[42] Zhang, J.-Y., Whalley, J.P., Knight, J.C., et al. (2023) SARS-CoV-2 Infection Induces a Long-Lived Pro-Inflammatory Transcriptional Profile. Genome Medicine, 15, Article No. 69. [Google Scholar] [CrossRef] [PubMed]
[43] WHO (2023) COVID-19 Advice for the Public: Getting Vaccinated.
https://www.who.int/zh/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines/advice
[44] Chen, J., Wang, R., Hozumi, Y., et al. (2022) Emerging Dominant SARS-CoV-2 Variants. Journal of Chemical Information and Modeling, 63, 335-342. [Google Scholar] [CrossRef] [PubMed]
[45] Nguyen, N.N., Nguyen, Y.N., Hoang, V.T., et al. (2023) SARS-CoV-2 Reinfection and Severity of the Disease: A Systematic Review and Meta-Analysis. Viruses, 15, Article No. 967. [Google Scholar] [CrossRef] [PubMed]
[46] Su, Y., Yuan, D., Chen, D.G., et al. (2022) Multiple Early Factors Anticipate Post-Acute COVID-19 Sequelae. Cell, 185, 881-895.E820. [Google Scholar] [CrossRef] [PubMed]
[47] Mollerup, A., Henriksen, M., Larsen, S.C., et al. (2021) Effect of PEP Flute Self-Care versus Usual Care in Early Covid-19: Non-Drug, Open Label, Randomised Controlled Trial in a Danish Community Setting. BMJ, 375, e066952. [Google Scholar] [CrossRef] 
[48] Levinstein Hallak, K. and Rosset, S. (2022) Statistical Modeling of SARS-CoV-2 Substitution Processes: Predicting the Next Variant. Communications Biology, 5, Article No. 285. [Google Scholar] [CrossRef] [PubMed]
[49] Keusch, G.T., Amuasi, J.H., Anderson, D.E., et al. (2022) Pandemic Origins and a One Health Approach to Preparedness and Prevention: Solutions Based on SARS-CoV-2 and Other RNA Viruses. Proceedings of the National Academy of Sciences, 119, e2202871119. [Google Scholar] [CrossRef] [PubMed]
[50] Chen, Z., Azman, A.S., Chen, X., et al. (2022) Global Landscape of SARS-CoV-2 Genomic Surveillance and Data Sharing. Nature Genetics, 54, 499-507. [Google Scholar] [CrossRef] [PubMed]
[51] Araf, Y., Akter, F., Tang, Y.D., et al. (2022) Omicron Variant of SARS-CoV-2: Genomics, Transmissibility, and Responses to Current COVID-19 Vaccines. Journal of Medical Virology, 94, 1825-1832. [Google Scholar] [CrossRef] [PubMed]
[52] Wang, Q., Iketani, S., Li, Z., et al. (2023) Alarming Antibody Evasion Properties of Rising SARS-CoV-2 BQ and XBB Subvariants. Cell, 186, 279-286.E278. [Google Scholar] [CrossRef] [PubMed]
[53] Carabelli, A.M., Peacock, T.P., Thorne, L.G., et al. (2023) SARS-CoV-2 Variant Biology: Immune Escape, Transmission and Fitness. Nature Reviews Microbiology, 21, 162-177. [Google Scholar] [CrossRef] [PubMed]
[54] Sulmasy, D.P. (2021) Are SARS-CoV-2 Human Challenge Trials Ethical? JAMA Internal Medicine, 181, 1031-1032. [Google Scholar] [CrossRef] [PubMed]
[55] Gruell, H., Vanshylla, K., Weber, T., et al. (2022) Antibody-Mediated Neutralization of SARS-CoV-2. Immunity, 55, 925-944. [Google Scholar] [CrossRef] [PubMed]
[56] 陈祺, 胡潇文, 黄兴成, 等. 新型冠状病毒肺炎长期健康损害的研究进展[J]. 病毒学报, 2023, 39(2): 509-516.
[57] Flacco, M.E., Acuti Martellucci, C., Baccolini, V., et al. (2022) Risk of Reinfection and Disease after SARS-CoV-2 Primary Infection: Meta-Analysis. European Journal of Clinical Investigation, 52, e13845. [Google Scholar] [CrossRef] [PubMed]
[58] Yüce, M., Filiztekin, E. and Özkaya, K.G. (2021) COVID-19 Diagnosis—A Review of Current Methods. Biosensors and Bioelectronics, 172, Article ID: 112752. [Google Scholar] [CrossRef] [PubMed]
[59] Ballouz, T., Menges, D., Anagnostopoulos, A., et al. (2023) Recovery and Symptom Trajectories up to Two Years after SARS-CoV-2 Infection: Population Based, Longitudinal Cohort Study. British Medical Journal, 381, Article No. 14. [Google Scholar] [CrossRef] [PubMed]
[60] Post, L., Marogi, E., Moss, C.B., et al. (2021) SARS-CoV-2 Surveillance in the Middle East and North Africa: Longitudinal Trend Analysis. Journal of Medical Internet Research, 23, E25830. [Google Scholar] [CrossRef] [PubMed]

为你推荐